Jan 08, 2024 / 05:00PM GMT
Christopher Thomas Schott - JPMorgan Chase & Co, Research Division - Senior Analyst
Good morning, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be introducing Amgen today. From the company, we have Bob Bradway, the company's Chairman and CEO. Obviously, a very productive 2023 for the company and really looking forward to Bob's comments as we think about the story going forward. So with that, I'll turn it over to Bob.
Robert A. Bradway - Amgen Inc. - Chairman, CEO & President
Okay. Good morning. Thank you, Chris, for your introduction, and thank you all for being here this morning. I would say heading into 2024 at Amgen, we're feeling very enthusiastic about the prospects of our being able to deliver attractive long-term growth for our shareholders and real value for the patients and staff at the company. So we're excited about the long-term outlook for our business, but also excited about what's in prospect in 2024.
Okay. You're familiar with the safe harbor statement. I'll move off that briskly. Let me just quickly remind you
Amgen Inc at JPMorgan Healthcare Conference Transcript
Jan 22, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers